These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 10417749

  • 21. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
    Victor-Vega C, Desai A, Montesinos MC, Cronstein BN.
    Inflammation; 2002 Feb; 26(1):19-24. PubMed ID: 11936752
    [Abstract] [Full Text] [Related]

  • 22. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial.
    Senet P, Vicaut E, Beneton N, Debure C, Lok C, Chosidow O.
    Arch Dermatol; 2011 Aug; 147(8):926-30. PubMed ID: 21482863
    [Abstract] [Full Text] [Related]

  • 23. Use of Regranex gel for diabetic foot ulcers.
    Piascik P.
    J Am Pharm Assoc (Wash); 1998 Aug; 38(5):628-30. PubMed ID: 9782698
    [No Abstract] [Full Text] [Related]

  • 24. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D.
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [Abstract] [Full Text] [Related]

  • 25. Topical becaplermin: new preparation. A slight short-term help for some diabetic patients.
    Prescrire Int; 2001 Dec; 10(56):167-9. PubMed ID: 11824438
    [Abstract] [Full Text] [Related]

  • 26. Use of topical recombinant human platelet-derived growth factor BB in abdominal wound separation.
    Shackelford DP, Fackler E, Hoffman MK, Atkinson S.
    Am J Obstet Gynecol; 2002 Apr; 186(4):701-4. PubMed ID: 11967494
    [Abstract] [Full Text] [Related]

  • 27. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008 Apr; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 29. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers.
    Hanft JR, Pollak RA, Barbul A, van Gils C, Kwon PS, Gray SM, Lynch CJ, Semba CP, Breen TJ.
    J Wound Care; 2008 Jan; 17(1):30-2, 34-7. PubMed ID: 18210954
    [Abstract] [Full Text] [Related]

  • 30. Role of platelet-derived growth factor as an adjunct to surgery in the management of pressure ulcers.
    Kallianinen LK, Hirshberg J, Marchant B, Rees RS.
    Plast Reconstr Surg; 2000 Nov; 106(6):1243-8. PubMed ID: 11083552
    [Abstract] [Full Text] [Related]

  • 31. Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.
    Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggers JP, Johnston AF, McHugh TP, Anthony MS, Robson LE.
    Ann Plast Surg; 1992 Sep; 29(3):193-201. PubMed ID: 1524367
    [Abstract] [Full Text] [Related]

  • 32. TGF-beta3 in the treatment of pressure ulcers: a preliminary report.
    Hirshberg J, Coleman J, Marchant B, Rees RS.
    Adv Skin Wound Care; 2001 Sep; 14(2):91-5. PubMed ID: 11899912
    [Abstract] [Full Text] [Related]

  • 33. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane.
    Yoon J, Giacopelli J, Granoff D, Kobayashi W.
    J Am Podiatr Med Assoc; 2002 Jun; 92(6):350-4. PubMed ID: 12070235
    [Abstract] [Full Text] [Related]

  • 34. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Jun; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 35. Re: Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.
    Brown GL.
    Ann Plast Surg; 1993 Feb; 30(2):192. PubMed ID: 8489189
    [No Abstract] [Full Text] [Related]

  • 36. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
    LeGrand EK.
    Am J Surg; 1998 Aug; 176(2A Suppl):48S-54S. PubMed ID: 9777972
    [Abstract] [Full Text] [Related]

  • 37. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 38. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
    Boykin JV.
    Adv Skin Wound Care; 2000 Oct; 13(4 Pt 1):169-74. PubMed ID: 11075012
    [Abstract] [Full Text] [Related]

  • 39. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J, Margolis DJ.
    Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
    [Abstract] [Full Text] [Related]

  • 40. Cost Effectiveness of Becaplermin Gel on Wound Closure for the Treatment of Pressure Injuries.
    Gilligan AM, Waycaster CR, Milne CT.
    Wounds; 2018 Jun; 30(6):197-204. PubMed ID: 29809161
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.